Who Paid My Doc
Shane Hollawell
Podiatrist, Foot & Ankle Surgery Manasquan, NJ Doctor of Podiatric Medicine
NPI 1740269273 CMS profile 260337
2315 Rt 34 So, Ste D, Manasquan, NJ 08736
General payments
$168,701
Research payments
$17,225
Ownership & investment interest
$3,944,048
Research they led as principal investigator
$10,389
Through program year 2025, Shane Hollawell of Manasquan, NJ is reported in the CMS Open Payments database as having received $168,701 across 241 general payments and $17,225 in research payments paid to them. Separately, studies naming them as principal investigator received $10,389 in research payments, paid to institutions rather than to them. They also declared ownership or investment interests valued at $3,944,048 across 14 holdings.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 98th percentile of Podiatrist, Foot & Ankle Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
16 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $15,638 | 29 | |
| 2024 | General | $12,435 | 24 | |
| 2023 | General | $40,405 | 50 | |
| 2023 | Research | $1,125 | 1 | |
| 2022 | General | $26,680 | 41 | |
| 2021 | General | $21,208 | 43 | |
| 2021 | Research | $16,100 | 1 | |
| 2020 | General | $29,474 | 25 | |
| 2019 | General | $22,862 | 29 | |
| 2025 | Ownership | $573,499 | 2 | |
| 2024 | Ownership | $575,970 | 2 | |
| 2023 | Ownership | $754,318 | 2 | |
| 2022 | Ownership | $760,524 | 2 | |
| 2021 | Ownership | $626,016 | 2 | |
| 2020 | Ownership | $340,094 | 2 | |
| 2019 | Ownership | $313,627 | 2 |
Beside peers
- Shane Hollawell
- Podiatrist, Foot & Ankle Surgery median
- Middle half of Podiatrist, Foot & Ankle Surgery
- National median
In program year 2025, general payments to Shane Hollawell were reported at $15,638. Among 6,994 Podiatrist, Foot & Ankle Surgery profiles paid that year, the median was $424 and the middle half received between $139 and $1,306.
Show as a table
| Year | Shane Hollawell | Podiatrist, Foot & Ankle Surgery median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $22,862 | $389 | $118–$1,406 | $163 |
| 2020 | $29,474 | $191 | $62–$691 | $114 |
| 2021 | $21,208 | $329 | $104–$1,341 | $132 |
| 2022 | $26,680 | $419 | $125–$1,611 | $149 |
| 2023 | $40,405 | $377 | $128–$1,164 | $160 |
| 2024 | $12,435 | $394 | $134–$1,168 | $164 |
| 2025 | $15,638 | $424 | $139–$1,306 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 3 drugsPart D claims
57
Drug cost
$279
Branded share of claims
0%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Mupirocin | Generic | 23 | $160 | |
| Methylprednisolone | Generic | 14 | $87 | |
| Ibuprofen | Generic | 20 | $32 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 66 billing codesPaid by Medicare
$108,650
Medicare patients
463
Services billed
2,375
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 62% | |
| Ischemic heart disease | 37% | |
| Diabetes | 26% | |
| Osteoporosis | 21% | |
| Depression | 19% | |
| Chronic kidney disease | 18% | |
| Cancer | 16% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, dexamethasone sodium phosphate, 1 mg J1100 | Office | 50 | 622 | $51 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
243 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Podiatrist, Foot & Ankle Surgery in New Jersey
John Cozzarelli
Podiatrist, Foot & Ankle Surgery · Belleville, NJ
Matthew Regulski
Podiatrist, Foot & Ankle Surgery · Toms River, NJ
Michael Subik
Podiatrist, Foot & Ankle Surgery · Lyndhurst, NJ
Krupa Patel
Podiatrist, Foot & Ankle Surgery · Morris Plains, NJ
Johanna Godoy
Podiatrist, Foot & Ankle Surgery · Wayne, NJ
Mark Solomon
Podiatrist, Foot & Ankle Surgery · Cedar Knolls, NJ
Related records
Podiatrist, Foot & Ankle Surgery in New Jersey
Practitioners in the same specialty and state, ranked by reported value.
All Podiatrist, Foot & Ankle Surgery
Everyone recorded under this specialty, nationwide.
Doctors in New Jersey
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.